Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD)
CUSIP: 74065P101
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock, $0.0001 par value per share
- Shares outstanding
- 65,427,364
- Total 13F shares
- 28,472,272
- Share change
- +1,310,394
- Total reported value
- $82,563,685
- Price per share
- $2.90
- Number of holders
- 48
- Value change
- +$4,105,718
- Number of buys
- 23
- Number of sells
- 22
Quarterly Holders Quick Answers
What is CUSIP 74065P101?
CUSIP 74065P101 identifies PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 74065P101:
Top shareholders of PRLD - Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Vaddi Krishna |
13D/G
|
— |
13%
|
6,745,647
|
$19,562,376 | +$1,008,643 | 31 Dec 2025 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
17%
|
10,909,256
|
$15,709,329 | — | 30 Sep 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
15%
|
10,123,824
|
$14,578,307 | — | 30 Sep 2025 | |
| INCYTE CORP |
13D/G
|
— |
9.9%
|
4,372,124
|
$6,295,859 | $0 | 03 Nov 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1.8%
|
1,147,044
|
$1,651,743 | — | 30 Sep 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.5%
|
992,854
|
$1,429,710 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.3%
|
876,338
|
$1,262,000 | — | 30 Sep 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.83%
|
544,000
|
$783,360 | — | 30 Sep 2025 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.83%
|
540,565
|
$777,000 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.43%
|
284,203
|
$409,252 | — | 30 Sep 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0.4%
|
264,973
|
$381,562 | — | 30 Sep 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.34%
|
222,700
|
$320,688 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.33%
|
217,568
|
$313,366 | — | 30 Sep 2025 | |
| TD ASSET MANAGEMENT INC |
13F
|
Company |
0.25%
|
160,652
|
$231,339 | — | 30 Sep 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.23%
|
152,233
|
$219,216 | — | 30 Sep 2025 | |
| Laurent Chardonnet |
3/4/5
|
Chief Financial Officer |
—
mixed-class rows
|
192,165
mixed-class rows
|
$158,962 | — | 01 Mar 2024 | |
| Jane Huang |
3/4/5
|
President, CMO |
—
mixed-class rows
|
305,667
mixed-class rows
|
$153,736 | — | 04 Oct 2025 | |
| Shay Capital LLC |
13F
|
Company |
0.15%
|
100,000
|
$144,000 | — | 30 Sep 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.15%
|
97,592
|
$140,532 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.12%
|
79,327
|
$114,231 | — | 30 Sep 2025 | |
| GSA CAPITAL PARTNERS LLP |
13F
|
Company |
0.11%
|
75,161
|
$108,000 | — | 30 Sep 2025 | |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE |
13F
|
Company |
0.11%
|
69,252
|
$99,723 | — | 30 Sep 2025 | |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.08%
|
53,500
|
$77,040 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.06%
|
36,421
|
$52,446 | — | 30 Sep 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.05%
|
34,822
|
$50,144 | — | 30 Sep 2025 | |
| Cerity Partners LLC |
13F
|
Company |
0.05%
|
34,333
|
$49,440 | — | 30 Sep 2025 | |
| PRUDENTIAL FINANCIAL INC |
13F
|
Company |
0.04%
|
25,840
|
$37,210 | — | 30 Sep 2025 | |
| HRT FINANCIAL LP |
13F
|
Company |
0.03%
|
16,901
|
$24,000 | — | 30 Sep 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.02%
|
15,578
|
$22,432 | — | 30 Sep 2025 | |
| HSBC HOLDINGS PLC |
13F
|
Company |
0.02%
|
13,747
|
$20,208 | — | 30 Sep 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.02%
|
10,500
|
$15,120 | — | 30 Sep 2025 | |
| Christopher Pierce |
3/4/5
|
EVP and Chief of Business Oper |
—
mixed-class rows
|
211,546
mixed-class rows
|
$14,138 | — | 02 Sep 2021 | |
| FMR LLC |
13F
|
Company |
0.01%
|
9,099
|
$13,103 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
8,848
|
$12,741 | — | 30 Sep 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.01%
|
8,712
|
$12,545 | — | 30 Sep 2025 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.01%
|
7,581
|
$11,000 | — | 30 Sep 2025 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.01%
|
6,927
|
$9,975 | — | 30 Sep 2025 | |
| CITIGROUP INC |
13F
|
Company |
0.01%
|
5,975
|
$8,604 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
0.01%
|
4,171
|
$6,006 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.01%
|
3,879
|
$5,585 | — | 30 Sep 2025 | |
| SBI Securities Co., Ltd. |
13F
|
Company |
0%
|
2,741
|
$3,947 | — | 30 Sep 2025 | |
| NISA INVESTMENT ADVISORS, LLC |
13F
|
Company |
0%
|
1,634
|
$2,353 | — | 30 Sep 2025 | |
| CWM, LLC |
13F
|
Company |
0%
|
1,219
|
$2,000 | — | 30 Sep 2025 | |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
|
Company |
0%
|
1,171
|
$1,686 | — | 30 Sep 2025 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
500
|
$720 | — | 30 Sep 2025 | |
| EverSource Wealth Advisors, LLC |
13F
|
Company |
0%
|
89
|
$128 | — | 30 Sep 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
52
|
$75 | — | 30 Sep 2025 | |
| Optiver Holding B.V. |
13F
|
Company |
0%
|
20
|
$29 | — | 30 Sep 2025 | |
| IFP Advisors, Inc |
13F
|
Company |
0%
|
18
|
$26 | — | 30 Sep 2025 | |
| Arax Advisory Partners |
13F
|
Company |
0%
|
15
|
$22 | — | 30 Sep 2025 |
Institutional Holders of Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD) as of Q4 2025
As of 31 Dec 2025,
Prelude Therapeutics Inc - Common Stock, $0.0001 par value per share (PRLD) was held by
48 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,472,272 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, BAKER BROS. ADVISORS LP, VANGUARD GROUP INC, Kynam Capital Management, LP, TWO SIGMA INVESTMENTS, LP, PRICE T ROWE ASSOCIATES INC /MD/, ACADIAN ASSET MANAGEMENT LLC, MORGAN STANLEY, MARSHALL WACE, LLP, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
48
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
45
Q4 2025 holders
48
Holder diff
3
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.